March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic®.

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

Novo Nordisk already has broad FDA approvals ... 2 diabetes who also have atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). It would become the first add-on ...

Novo Nordisk said the Food and ... failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday. The approval makes Ozempic the most broadly indicated GLP-1 drug ...

Ozempic will become the first and only GLP-1 receptor agonist to show lowering of risk of kidney disease progression in adults with Type 2 diabetes and chronic kidney disease.” Novo Nordisk has ...

Novo Nordisk and Eli Lilly are ... what it sees as abuses in the patent system. Ozempic, which also has approvals in chronic kidney disease and heart disease, accounted for about half of that ...

Novo Nordisk A/S NVO on Saturday presented ... events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD). The SOUL trial achieved its primary ...

Novo Nordisk on Saturday ... the cardiovascular rather than kidney benefits of the pill, Gough said. Ozempic is already approved to treat chronic kidney disease in diabetes patients.